Treatment of radioiodine-negative bone metastasis from papillary thyroid carcinoma with percutaneous ethanol injection therapy

Annals of Nuclear Medicine (Impact Factor: 1.68). 12/1996; 10(4):441-444. DOI: 10.1007/BF03164808


A 62-year-old woman with metastatic papillary thyroid carcinoma in the sternum was successfully treated with percutaneous
ethanol injection therapy (PEIT) when previous radioiodine therapy and external irradiation were ineffective. The patient
tolerated the treatment well and the refractory pain in the anterior chest wall that was alleviated with morphine prior to
PEIT completely disappeared. No severe complications were observed. PEIT was performed 4 times (2 times with ultrasound guidance
and 2 times with CT guidance). The posttreatment CT scan and201T1 scintigraphy demonstrated significant decrease in the tumor volume. The serum thyroglobulin level fell to less than one-twentieth
of the pretreatment value. It is suggested that PEIT has a value in treating bone metastasis from thyroid carcinoma which
do not respond to radioiodine.

1 Read
  • Source
    • "Other options include percutaneous ethanol injection and radiofrequency ablation (RFA) as their efficacy have been shown in several studies [7] [8] [9]. The decision for further adjuvant RAI therapy after reoperative neck dissection depends on the completeness of the dissection [5]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the majority of papillary thyroid carcinoma could be successfully managed by complete surgical resection alone or resection followed by radioiodine ablation, a small proportion of patients may develop radioiodine-refractory progressive disease which is not amenable to surgery, local ablative treatment or other treatment modalities. The use of FDG-PET/CT scan for persistent/recurrent disease has improved the accuracy of restaging as well as cancer prognostication. Given that patients with RAI-refractory disease tend to do significantly worse than those with radioiodine-avid or non-progressive disease, an increasing number of phase I and II studies have been conducted to evaluate the efficacy of new molecular targeted drugs such as the tyrosine kinase inhibitors and redifferentiation drugs. The overall response rate of these drugs ranged between 0-53%, depending on whether the patients had been previously treated with these drugs, performance status and extent of disease. However, drug toxicity remains a major concern in administration of target therapies. Nevertheless, there are also ongoing phase III studies evaluating the efficacy of these new drugs. The aim of the review was to summarize and discuss the results of these targeted drugs and redifferentiation agents for patients with progressive, radioiodine-refractory papillary thyroid carcinoma.
    Full-text · Article · Dec 2012 · Journal of Thyroid Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of the thyroid is required in a number of clinical situations (Freitas and Freitas 1994), i.e., clinically solitary thyroid nodule, superior mediastinal mass, hyperthyroidism, diagnosis and postoperative follow-up of thyroid carcinoma, neonatal hypothyroidism, and anomalous thyroid development.
    No preview · Chapter · Jan 1999
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 54-year-old man with medullary thyroid carcinoma in the thyroid gland was unable to undergo total thyroidectomy because the tumor had invaded the mediastinum. Radiation therapy and chemotherapy were given. Seven years later, intractable diarrhea and abdominal pain appeared, and computed tomography demonstrated hypervascular tumors in the thyroid gland and in the liver. The tumors were successfully treated with percutaneous ethanol injection to a lesion in the thyroid gland and transcatheter arterial embolization followed by percutaneous ethanol injection to tumors in the liver. Transcatheter arterial embolization and percutaneous ethanol injection may be valuable in treating medullary thyroid carcinoma.
    No preview · Article · Feb 1999 · Internal Medicine
Show more